NCT05629546招募中1 期
Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- For treatment with cells from an autologous source: Incidence and severity of adverse events
研究概览
简要总结
This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of histologically confirmed advanced or metastatic melanoma that has progressed after at least 12 weeks or a minimum of 2 doses of treatment with a standard of care PD1/PDL1 containing therapy (nivolumab, pembrolizumab, atezolizumab, or durvalumab).
- •Age: ≥18 years of age
- •Have an Eastern Cooperative Oncology Group Performance Status (ECOG) ≤ 2 at screening Form Arm 1 only: Patients must meet the eligibility criteria to undergo apheresis to obtain autlogous NK cells.
- •For Arm 2 only: Patient must have an available allogeneic NK cell donor who meets the eligibility criteria.
- •Adequate organ function as defined below:
- •Total bilirubin < 2 mg/dL
- •AST(SGOT)/ALT(SGPT) < 3.0 x ULN
- •Creatinine within normal institutional limits OR creatinine clearance > 40 mL/min/1.73 m^2 by Cockcroft-Gault Formula
- •Oxygen saturation ≥ 90% on room air
- •Ejection fraction ≥ 45%
- •Patients with a prior history of symptomatic CNS metastases must have received treatment and be neurologically stable for at least for 4 weeks and off anti-seizure medication and steroids for 7 days prior to initiation of LDC.
- •Able to be off corticosteroids and any other immune suppressive medications for at least 14 days prior to apheresis or lymphodepletion and continuing until 30 days after the infusion of the ML NK cells. However, use of physiological dosing of corticosteroids (defined as ≤15mg prednisone or equivalent) is permitted if deemed medically necessary.
- •Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, throughout participation in the study and for at least 5 months after the last dose of relatlimab.
- •Life expectancy >12 weeks
- •Ability to understand and willingness to sign an IRB approved written informed consent document
排除标准
- •Active autoimmune disorder requiring immunosuppression (physiologic steroids defined as ≤15mg prednisone or equivalent are acceptable).
- •Prior history of an immune-related Grade 3 or 4 AE attributed to prior cancer immunotherapy (other than endocrinopathy managed with either replacement therapy or asymptomatic elevation of serum amylase or lipase) that resulted in permanent discontinuation of the prior immunotherapeutic agent.
- •Patients with Grade ≤2 irAE who have not completely recovered from irAE (i.e. have residual toxicities >Grade 1) related to prior cancer immunotherapy (other than endocrinopathy management with replacement therapy or stable vitiligo). Patients treated with corticosteroids for irAE must demonstrate absence of related signs or symptoms for ≥7 days following discontinuation of corticosteroids.
- •Leptomeningeal disease, carcinomatous meningitis, or symptomatic CNS metastases. Patients with asymptomatic brain metastasis with no pending intervention needed, or patients with treated CNS disease and stable for at least 4 weeks and off anti-seizure medication and steroids for 7 days prior to initiation of LDC are eligible.
- •Known hypersensitivity to one or more of the study agents.
- •Comorbidities and any conditions, that in the opinion of the investigator, that put the subject at unacceptable risk for study therapy or prevent the participant from consenting or participating in the study.
- •Uncontrolled and active systemic infections, including but not limited to HIV, Hepatitis B or C infection.
- •Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.
- •New progressive pulmonary infiltrates concerning for new or uncontrolled infectious process. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections).
- •Received any investigational or off-label drugs, or cytotoxic chemotherapy within the 14 days or five half-lives (whichever is greater) prior to apheresis.
- •Pregnant or breastfeeding.
- •Subjects are not acceptable candidates if they received prior tumor infiltrating lymphocytes (TIL) therapy (either in the setting of clinical trial or standard of care if TIL therapy is FDA approved in the future), or an organ allograft.
- •Has a known additional malignancy that is progressing or required active treatment within the past 2 years. Note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg. Breast carcinoma, cervical cancer in situ) that has undergone potentially curative therapy are not excluded.
- •Received a live or attenuated vaccine within 28 days prior to the beginning of the lymphodepletion therapy.
- •Eligibility Criteria for Haploidentical Donors (For Arm 2 only)
- •Donor must be at least 18 years of age.
- •Donor must be willing, in general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
- •Donor must be negative for hepatitis, HTLV, and HIV on donor viral screen.
- •Donor may not be pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 30 days prior to apheresis.
- •Donor must be able to understand and willing to sign an IRB-approved written informed consent document.
- •Only haploidentical donors will be included.
- •Donor must meet the requirements of institutional donor guidelines, including the requirements of Foundation for the Accreditation of Hematopoietic Cell Therapy (FACT) criteria.
- •Eligibility Criteria for Autologous Patients (For Arm 1 only)
- •Patient must be willing and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
- •Patient must be negative for hepatitis, HTLV, and HIV on the viral screen.
- •Patient may not be treated with any cytotoxic treatment within 2 weeks prior to leukapheresis.
研究组 & 干预措施
Arm 1: Autologous: Memory-like natural killer cells + nivolumab + relatilimab
Experimental
- Subjects enrolled into arm 1 will receive autologous ML NK cells on Day 0.
- Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier.
干预措施: Nivolumab (Biological)
Arm 1: Autologous: Memory-like natural killer cells + nivolumab + relatilimab
Experimental
- Subjects enrolled into arm 1 will receive autologous ML NK cells on Day 0.
- Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier.
干预措施: Cytokine-induced memory-like natural killer cells (Biological)
Arm 1: Autologous: Memory-like natural killer cells + nivolumab + relatilimab
Experimental
- Subjects enrolled into arm 1 will receive autologous ML NK cells on Day 0.
- Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier.
干预措施: Relatilmab (Biological)
结局指标
主要结局
For treatment with cells from an autologous source: Incidence and severity of adverse events
时间窗: From start of treatment through end of safety follow-up (estimated to be 15 months)
-As determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
For treatment with cells from an allogeneic source: Incidence and severity of adverse events
时间窗: From start of treatment through end of safety follow-up (estimated to be 15 months)
-As determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
次要结局
- Disease control rate (DCR)(Through completion of follow-up (estimated to be 3 years))
- Overall survival (OS)(Through completion of follow-up (estimated to be 3 years))
- Objective response rate (ORR)(Through completion of treatment (estimated to be 12 months))
- Duration of response (DOR)(Through completion of follow-up (estimated to be 3 years))
- Progression-free survival (PFS)(Through completion of follow-up (estimated to be 3 years))
研究者
研究点 (2)
Loading locations...
相似试验
暂停
1 期
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on CancerHepatocellular CancerSquamous Cell Lung CancerBreast CancerProstate CancerPancreatic CancerColon CancerGliomaNCT00909558Envita Medical Center, Inc.24
进行中（未招募）
早期 1 期
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial CarcinomaRenal CarcinomaRenal Cell CarcinomaNCT06318871Dana-Farber Cancer Institute5
招募中
1 期
Autologous Natural Killer Cell Therapy for Hepatocellular CarcinomaHepatocellular CarcinomaNCT06044506Dr Cipto Mangunkusumo General Hospital3
撤回
1 期
IIT PH1 KDS-1001 in Patients With CMLCML (Chronic Myelogenous LeukemiaNCT04808115Duke University12
已完成
1 期
Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT03366064Asan Medical Center5